

Ref: FOI/GS/ID 4723

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone  
Kent  
ME16 9QQ

Email: mtw-tr.foiadmin@nhs.net

7 June 2018

### **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Metastatic Squamous Cell Non-Small cell lung cancer.

*You asked:*

*Metastatic Squamous Cell Non-small cell lung cancer (NSCLC):*

*1. In the past 3 months, how many patients were treated with?*

*Atezolizumab (Tecentriq)*

*Pembrolizumab (Keytruda)*

*Nivolumab (Opdivo)*

*Other active systemic anti-cancer therapy*

*Palliative care only*

*Metastatic Non Squamous Cell Non-small cell lung cancer (NSCLC):*

*2. In the past 3 months, how many patients were treated with?*

*Atezolizumab (Tecentriq)*

*Pembrolizumab (Keytruda)*

*Nivolumab (Opdivo)*

*Other active systemic anti-cancer therapy*

*Palliative care only*

*Adjuvant Melanoma*

*3. In the past three months how many patients were seen who had stage III resectable melanoma?*

*4. Of all stage III patients seen, how many received a complete resection?*

*5. Of all stage III patients seen, how many were stage III a?*

### **Trust response:**

#### **Metastatic Squamous Cell Non-small cell lung cancer (NSCLC):**

In the past 3 months, how many patients were treated with?

Atezolizumab (Tecentriq)	
Pembrolizumab (Keytruda)	1
Nivolumab (Opdivo)	1
Other active systemic anti-cancer therapy	2
Palliative care only	

**Metastatic Non Squamous Cell Non-small cell lung cancer (NSCLC):**

In the past 3 months, how many patients were treated with?

Atezolizumab (Tecentriq)	0
Pembrolizumab (Keytruda)	12
Nivolumab (Opdivo)	0
Other active systemic anti-cancer therapy	19
Palliative care only	

**Adjuvant Melanoma**

The Trust is not commissioned to provide dermatology services.